MolecularMatch Announces Issuance of US Patent for its Precision Medicine Service

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

HOUSTON, Aug. 8, 2019 /PRNewswire/ — MolecularMatch, a leading clinical informatics company providing Precision Medicine software solutions for oncology, announced today that the United States Patent and Trademark Office has issued US Patent 10,360,349 covering its Precision Medicine Service for use by hospitals, pharmaceutical companies, laboratories, health information systems and the broader clinical informatics industry.

MolecularMatch Logo (PRNewsfoto/MolecularMatch)MolecularMatch Logo (PRNewsfoto/MolecularMatch)

This latest patent covers the foundational technology for therapeutic guidance and clinical trial matching in MolecularMatch’s MM-Power and MM-Portal products.

“The Precision Medicine Service patent covers the process of data acquisition, curation and validation of our industry leading clinico-biological knowledge platform. It includes a state-of-the-art search engine designed to rank clinical relevance to a patient’s medical profile, providing real-time search results of treatment options inclusive of clinical trials,” said Nick Tackes, CTO at MolecularMatch. “Furthermore, our patent covers our clinical trial enrollment technology which is designed to expedite what is often a protracted process.” 

“This patent is an important component as we continue to build upon strategic and technological advancements for our clinical decision support solutions,” said Eric Pulaski, President at MolecularMatch.

About MolecularMatch

MolecularMatch, Inc. is a Houston, Texas based clinical informatics SaaS company established in 2014 out of MD Anderson Cancer Center. The company was founded on the vision of using tumor molecular profiling and outcomes from previously-treated patients to provide the best personalized treatment for current patients. MolecularMatch delivers personalized, evidence-based therapeutic guidance and clinical trials matched to each patient. Customers include genetic labs, health information systems, biopharma, hospitals and cancer centers. Visit us at molecularmatch.com or follow us on Twitter or LinkedIn.

Scott L. Bender
MolecularMatch
+1-214-435-4498
sbender@molecularmatch.com

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/molecularmatch-announces-issuance-of-us-patent-for-its-precision-medicine-service-300898360.html

SOURCE MolecularMatch

Staff

Recent Posts

CORRECTING and REPLACING Vouched Developing Integration in Epic Toolbox Under Construction for Remote Identity Verification

Integration Empowers Hospitals to Streamline Patient Onboarding, Enhance Compliance, and Improve Care Delivery with Seamless…

2 hours ago

BLUE & CO., LLC PROVIDES NOTICE OF DATA EVENT

CARMEL, Ind., July 3, 2025 /PRNewswire/ -- Blue & Co., LLC ("Blue") is a financial…

5 hours ago

Dr. Aubrey de Grey Brings Cutting-Edge Science to RAADfest 2025: LEV Foundation Partners with Coalition for Radical Life Extension

Renowned biogerontologist Dr. Aubrey de Grey to curate specialized scientific programming at world's leading longevity…

5 hours ago

NervGen Strengthens Board Leadership to Accelerate Clinical and Corporate Growth

Dr. Adam Rogers appointed chair as company advances toward key milestones following positive topline chronic…

6 hours ago

ScienceSoft Raises the Bar for AI Voice Scheduling in Healthcare

MCKINNEY, Texas--(BUSINESS WIRE)--#AI--Human-Like, Real-Time AI Scheduler launched by ScienceSoft ScienceSoft has introduced a HIPAA-compliant AI…

8 hours ago

New Podcast “Spreading the Good BUZZ” Hosted by Josh and Heidi Case Launches July 7th with Explosive Global Reach and a Mission to Transform Lives

Through Hope and Community in Recovery, Sober.Buzz along with @SoberBuzzToken on Instagram are Impacting and…

11 hours ago